MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • MassDevice Today
    • Cardiovascular
    • Clinical Trials
    • Legal News
    • Orthopedics
    • Regulatory/Compliance
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • More MedTech
    • Cosmetic/Aesthetic
    • Diabetes
    • Dialysis
    • Distribution
    • Imaging
    • Otolaryngology Ear, Nose & Throat
    • Pharma
    • Respiratory
    • Wound Care
  • Blog
  • DeviceTalks Podcasts
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • Videos
    • White Papers
  • DeviceTalks

Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US

August 30, 2018 By Fink Densford Leave a Comment

Otsuka Pharmaceutical (TYO:4578) said today it inked a collaborative deal with health management group Magellan Health to distribute its drug-device combo Abilify Mycite in the US. The Tokyo-based pharmaceutical company touted the Abilify Mycite system as the first FDA-approved drug-device combo designed to track drug ingestion, and said that the tracking data will be integrated into […]

Filed Under: Business/Financial News, Distribution, Drug-Device Combinations, Neurological Tagged With: Otsuka Holdings

The 10 most innovative medical devices of 2018

August 3, 2018 By Danielle Kirsh Leave a Comment

The nominees for the best medical technology of 2018 were recently announced for the 12th Annual Prix Galien USA Awards. The host of the awards, The Galien Foundation, awards the Prix Galien Award annually to examples of outstanding biomedical and technology product achievements that are designed to improve human condition. Before the candidates can qualify […]

Filed Under: Diabetes, Diagnostics, Drug-Device Combinations, Imaging, mHealth (Mobile Health), Neurological, Patient Monitoring Tagged With: Abbott, Boston Scientific, BrainScope, Foundation Medicine, Integra LifeSciences, Koning Corp., MedTech, Medtronic, Otsuka Holdings, The Galien Foundation

Otsuka to acquire renal denervation firm ReCor Medical

July 10, 2018 By Brad Perriello Leave a Comment

Otsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension. Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients […]

Filed Under: Mergers & Acquisitions, Ultrasound, Wall Street Beat Tagged With: Hypertension, Otsuka Holdings, ReCor Medical, Renal

Otsuka Holdings to shift ReCor rights to medical device subsidiary

November 14, 2017 By Fink Densford Leave a Comment

Otsuka Holdings said this week it plans to move renal denervation assets it acquired commercialization rights it acquired last year to its wholly-owned subsidiary, Otsuka Medical Devices. The Japan-based company acquired the rights to commercialize ReCor Medical’s renal denervation technology last May after having invested in the company in 2014. Otsuka said that its board […]

Filed Under: Business/Financial News Tagged With: Otsuka Holdings

FDA approves first pill with sensor to track ingestion

November 14, 2017 By Sarah Faulkner Leave a Comment

The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Patient Monitoring, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Otsuka Holdings, Proteus Digital Health

Injectable, extended-release bipolar drug wins FDA nod

July 31, 2017 By Sarah Faulkner Leave a Comment

Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Food & Drug Administration (FDA), Neurological, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Lundbeck, Otsuka Holdings

Proteus, Otsuka take another run at FDA approval for Abilify-smart pill combo

May 23, 2017 By Sarah Faulkner Leave a Comment

Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said today that the FDA accepted its resubmitted new drug application for their “smart pill”. The drug-device product combines Abilify and a Proteus ingestible sensor in a single tablet. The FDA is slated to make a decision on the NDA resubmission in the 4th quarter this year. Get the […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Otsuka Holdings, Proteus Digital Health

Otsuka gets in on ReCor Medical’s Paradise renal denervation device

May 16, 2016 By Mark Hollmer Leave a Comment

ReCor Medical said it landed a strategic investment from Japanese conglomerate Otsuka Pharmaceutical (TYO:4578) that will bring to Asia its Paradise renal denervation device for treating hypertension. Neither side is disclosing financial terms, but the deal calls for Otsuka to receive exclusive rights to pursue clinical trials, regulatory approval and commercialization of ReCor’s Paradise device in Japan, China, Korea […]

Filed Under: Clinical Trials, Drug-Device Combinations, Funding Roundup, Pharmaceuticals Tagged With: Otsuka Holdings, ReCor Medical

FDA wants more from Proteus, Otsuka on ‘smart pill’

April 27, 2016 By Fink Densford Leave a Comment

Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health  said today that the FDA issued a complete response letter requesting more information from the companies for the combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug. The Proteus pill is designed to signal a wearable patch after it reaches the stomach, recording and time-stamping data from […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA) Tagged With: Otsuka Holdings, Proteus Digital Health

FDA to review Proteus ‘smart pill’ with Otsuka’s Abilify anti-depressant

September 11, 2015 By Brad Perriello Leave a Comment

Otsuka Pharmaceutical (TYO:4578) and Proteus Digital Health said yesterday that the FDA will review a combination of the Proteus “smart pill” and Otsuka’s Abilify anti-depressant drug. The companies said the FDA accepted their new drug application for the drug-device combination, using the Proteus ingestible sensor and Otsuka’s aripiprazole drug in patients with serious mental illnesses such as major […]

Filed Under: Drug-Device Combinations Tagged With: Otsuka Holdings, Proteus Digital Health

Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us
Privacy
Add us on FacebookMassDevice Network
Follow us on Twitter@MassDevice
Connect with us on LinkedInLinkedIn
Follow us on YouTube YouTube

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS